



**REVIEW ARTICLE**

**Matrix Type Drug Delivery System: A Review**

**Pandya BD<sup>1\*</sup> Shah CJ<sup>2</sup>**

<sup>1</sup> *Gitanjali Pharmacy College, Talod, Sabarkantha, Gujarat, India.*

<sup>2</sup> *K.B.Raval College of Pharmacy, Shertha, Gandhinagar, Gujarat, India.*

Manuscript No: IJPRS/V1/I4/00203, Received On: 08/11/2012, Accepted On: 11/11/2012

**ABSTRACT**

An appropriately designed controlled release drug delivery system can be a major advance towards solving problems concerning the targeting of a drug towards specific organ or a tissue and controlling the rate of drug delivery to the target tissue. Matrix tablet is an interesting option when developing as oral controlled release formulation. The Present study focus on oral controlled release dosage forms and types of various polymers used to formulate Matrix Tablets. The use of polymer in controlling the release of drug has become important in the formulation of pharmaceuticals.

**KEYWORDS**

Polymer, Therapeutic, Matrices, Diffusion, Erosion, Dissolution

**INTRODUCTION**

Oral drug delivery is the most widely utilized route of administration among all the routes [nasal, ophthalmic, rectal, transdermal and Parental routes] that have been explored for systemic delivery of drugs via pharmaceutical products of different dosage form. Oral route is considered most natural, uncomplicated, convenient and safe [in respect to Parental route] due to its ease of administration, patient acceptance, and cost-effective manufacturing process.<sup>1</sup>

Pharmaceutical products designed for oral delivery are mainly immediate release type or conventional drug delivery systems, which are designed for immediate release of drug for rapid absorption. These immediate release dosage forms have some limitations such as: <sup>2</sup>

1) Drugs with short half-life requires frequent administration, which increases chances of missing dose of drug leading to poor patient compliance.

- 2) A typical peak-valley plasma concentration-time profile is obtained which makes attainment of steady state condition difficult.
- 3) The unavoidable fluctuations in the drug concentration may lead to under medication or overmedication as the CSS values fall or rise beyond the therapeutic range.
- 4) The fluctuating drug levels may lead to precipitation of adverse effects especially of a drug with small therapeutic index, whenever overmedication occurs.

In order to overcome the drawbacks of conventional drug delivery systems, several technical advancements have led to the development of controlled drug delivery system that could revolutionize method of medication and provide a number of therapeutic benefits.<sup>3</sup>

**Controlled Drug Delivery Systems**

Controlled drug delivery systems have been developed which are capable of controlling the rate of drug delivery, sustaining the duration of therapeutic activity and/or targeting the delivery of drug to a tissue.<sup>4</sup>

**\*Address for Correspondence:**

**Bhaumik D. Pandya**

Gitanjali Pharmacy College,  
Talod, Sabarkantha,  
Gujarat, India .

E-Mail Id: [bhaumik3890@gmail.com](mailto:bhaumik3890@gmail.com)

Controlled drug delivery or modified drug delivery systems are conveniently divided into four categories.

- 1) Delayed release
- 2) Sustained release
- 3) Site-specific targeting
- 4) Receptor targeting

#### **Factors Affecting the Design and Performance of Controlled Drug Delivery<sup>4</sup>**

##### 1. Drug Properties

- Partition coefficient
- Drug stability
- Protein binding
- Molecular size and diffusivity

##### 2. Biological Properties

- Absorption
- Metabolism
- Elimination and biological half life
- Dose size
- Route of administration
- Target sites
- Acute or chronic therapy
- Disease condition

#### **Matrix Tablets**

One of the least complicated approaches to the manufacture of controlled release dosage forms involves the direct compression of blend of drug, retardant material and additives to formulate a tablet in which the drug is embedded in a matrix of the retardant. Alternatively drug and retardant blend may be granulated prior to compression.<sup>5</sup>

These are the type of controlled drug delivery systems, which release the drug in continuous manner by both dissolution controlled as well as diffusion controlled mechanisms. To control the release of the drugs, which are having different solubility properties, the drug is dispersed in

swellable hydrophilic substances, an insoluble matrix of rigid non swellable hydrophobic materials or plastic materials.<sup>6-7</sup>

One of the least complicated approaches to the manufacture of sustained release dosage forms involves the direct compression of blend of drug, retardant material and additives to formulate a tablet in which the drug is embedded in a matrix of the retardant. Alternatively drug and retardant blend may be granulated prior to compression. The materials most widely used in preparing matrix systems include both hydrophilic and hydrophobic polymers. Commonly available hydrophilic polymers include Hydroxypropylmethylcellulose (HPMC), Hydroxypropylcellulose (HPC), Hydroxyethyl cellulose (HEC), Xanthan gum, Sodium alginate, Poly (ethylene oxide) and cross-linked homopolymers and copolymers of Acrylic acid. It is usually supplied in micronized forms because small particle size is critical to the rapid formation of gelatinous layer on the tablet surface.<sup>8-10</sup>

Introduction of matrix tablet as sustained release (SR) has given a new breakthrough for novel drug delivery system (NDDS) in the field of Pharmaceutical technology. It excludes complex production procedures such as coating and pelletization during manufacturing and drug release rate from the dosage form is controlled mainly by the type and proportion of polymer used in the preparations. Hydrophilic polymer matrix is widely used for formulating an SR dosage form.<sup>11-15</sup>

Because of increased complication and expense involved in marketing of new drug entities, has focused greater attention on development of sustained release or controlled release drug delivery systems.<sup>16</sup>

Matrix systems are widely used for the purpose of sustained release. It is the release system which prolongs and controls the release of the drug that is dissolved or dispersed. In fact, a matrix is defined as a well-mixed composite of one or more drugs with gelling agent i.e. hydrophilic polymers.<sup>17</sup>

By the sustained release method therapeutically effective concentration can be achieved in the systemic circulation over an extended period of time, thus achieving better compliance of patients. Numerous SR oral dosage forms such as membrane controlled system, matrices with water soluble/insoluble polymers or waxes and osmotic systems have been developed, intense research has recently focused on the designation of SR systems for poorly water soluble drugs.<sup>18</sup>

### Objectives<sup>18</sup>

Recently, controlled release drug delivery has become the standards in the modern pharmaceutical design and intensive research has been undertaken in achieving much better drug product effectiveness, reliability and safety. Oral sustain release drug delivery medication will continue to account for the largest share of drug delivery systems. Hence in this work to formulate tablets in order to avoid the first pass metabolism and increase the bioavailability. Hence in this work an attempt was made to formulate sustain release system for in order to achieve even plasma concentration profile up to 24 hrs. Reason for the selection of -API as a model drug,

- Being BCS class II drug it is low soluble in water and highly permeable. And it is necessary to sustain the drug release.
- Bioavailability after oral administration is 20% Silent features to design formulation in sustain release tablets.
- Less risk of dose dumping.
- Less inter and intra subject variability.
- High degree of dispersion in the digestive tract thus minimizing the risk of high local drug concentrations.
- Drug may reach the site of optimum absorption in a reproducible fashion so reproducible bioavailability.
- Transport of drug is independent of gastric emptying.

### Drawback of Conventional Dosage Form<sup>19</sup>

- Poor patient compliance, increased chances of missing the dose of a drug with short half life for which frequent administration is necessary.
- The unavoidable fluctuations of drug concentration may lead to under medication or over medication.
- A typical peak-valley plasma concentration time profile is obtained which makes attainment of steady-state condition difficult.

### Advantages of Matrix Tablet<sup>20-21</sup>

- Easy to manufacture
- Versatile, effective and low cost
- Can be made to release high molecular weight compounds
- The sustained release formulations may maintain therapeutic concentrations over prolonged periods.
- The use of sustain release formulations avoids the high blood concentration.
- Sustain release formulations have the potential to improve the patient compliance.
- Reduce the toxicity by slowing drug absorption.
- Increase the stability by protecting the drug from hydrolysis or other derivative changes in gastrointestinal tract.
- Minimize the local and systemic side effects.
- Improvement in treatment efficacy.
- Minimize drug accumulation with chronic dosing.
- Usage of less total drug.
- Improvement the bioavailability of some drugs.
- Improvement of the ability to provide special effects. Ex: Morning relief of arthritis through bed time dosing.

### Disadvantages of Matrix Tablet<sup>20-21</sup>

- The remaining matrix must be removed after the drug has been released.
- High cost of preparation.
- The release rates are affected by various factors such as, food and the rate transit through the gut.
- The drug release rates vary with the square root of time. Release rate continuously diminishes due to an increase in diffusional resistance and/or a decrease in effective area at the diffusion front. However, a substantial sustained effect can be produced through the use of very slow release rates, which in many applications are indistinguishable from zero-order.

### Classification of Matrix Tablets

#### On the Basis of Retardant Material Used

Matrix tablets can be divided in to 5 types.<sup>22-24</sup>

#### 1. *Hydrophobic Matrices (Plastic matrices)*<sup>22</sup>

The concept of using hydrophobic or inert materials as matrix materials was first introduced in 1959. In this method of obtaining sustained release from an oral dosage form, drug is mixed with an inert or hydrophobic polymer and then compressed in to a tablet. Sustained release is produced due to the fact that the dissolving drug has diffused through a network of channels that exist between compacted polymer particles. Examples of materials that have been used as inert or hydrophobic matrices include polyethylene, polyvinyl chloride, ethyl cellulose and acrylate polymers and their copolymers. The rate-controlling step in these formulations is liquid penetration into the matrix. The possible mechanism of release of drug in such type of tablets is diffusion. Such types of matrix tablets become inert in the presence of water and gastrointestinal fluid.

#### 2. *Lipid Matrices*<sup>23</sup>

These matrices prepared by the lipid waxes and related materials. Drug release from such matrices occurs through both pore diffusion and

erosion. Release characteristics are therefore more sensitive to digestive fluid composition than to totally insoluble polymer matrix. Carnauba wax in combination with stearyl alcohol or stearic acid has been utilized for retardant base for many sustained release formulation.

#### 3. *Hydrophilic Matrices*<sup>24</sup>

Hydrophilic polymer matrix systems are widely used in oral controlled drug delivery because of their flexibility to obtain a desirable drug release profile, cost effectiveness, and broad regulatory acceptance. The formulation of the drugs in gelatinous capsules or more frequently, in tablets, using hydrophilic polymers with high gelling capacities as base excipients is of particular interest in the field of controlled release. In fact a matrix is defined as well mixed composite of one or more drugs with a gelling agent (hydrophilic polymer). These systems are called swellable controlled release systems. The polymers used in the preparation of hydrophilic matrices are divided in to three broad groups,

**A. Cellulose Derivatives:** Methylcellulose 400 and 4000cPs, Hydroxyethylcellulose; Hydroxypropylmethylcellulose (HPMC) 25, 100, 4000 and 15000cPs; and Sodium carboxymethylcellulose.

**B. Non Cellulose Natural or Semi Synthetic Polymers:** Agar-Agar; Carob gum; Alginates; Molasses; Polysaccharides of mannose and galactose, Chitosan and Modified starches.

**Polymers of acrylic acid:** Carbopol-934, the most used variety.

#### 4. *Biodegradable Matrices*<sup>24</sup>

These consist of the polymers which comprised of monomers linked to one another through functional groups and have unstable linkage in the backbone. They are biologically degraded or eroded by enzymes generated by surrounding living cells or by nonenzymetic process in to oligomers and monomers that can be metabolized or excreted. Examples are natural polymers such as proteins and polysaccharides; modified natural polymers; synthetic polymers

such as aliphatic poly (esters) and poly anhydrides.

### 5. Mineral Matrices<sup>24</sup>

These consist of polymers which are obtained from various species of seaweeds. Example is Alginic acid which is a hydrophilic carbohydrate obtained from species of brown seaweeds (Phaeophyceae) by the use of dilute alkali.

#### On the Basis of Porosity of Matrix<sup>25-28</sup>

Matrix system can also be classified according to their porosity and consequently, Macro porous; Micro porous and Non-porous systems can be identified:

##### 1. Macro Porous Systems

In such systems the diffusion of drug occurs through pores of matrix, which are of size range 0.1 to 1  $\mu\text{m}$ . This pore size is larger than diffusant molecule size.

##### 2. Micro Porous System

Diffusion in this type of system occurs essentially through pores. For micro porous systems, pore size ranges between 50 – 200  $\text{A}^\circ$ , which is slightly larger than diffusant molecules size.

##### 3. Non-porous System

Non-porous systems have no pores and the molecules diffuse through the network meshes. In this case, only the polymeric phase exists and no pore phase is present.

#### Polymers Used in Matrix Tablet<sup>29</sup>

**Hydrogels** Polyhydroxyethylmethacrylate (PHEMA), Cross-linked polyvinyl alcohol (PVA), Cross-linked polyvinyl pyrrolidone (PVP), Polyethylene oxide (PEO), Polyacrylamide (PA)

**Soluble polymers** Polyethyleneglycol (PEG), polyvinyl alcohol (PVA), Polyvinylpyrrolidone (PVP), Hydroxypropyl methyl cellulose (HPMC)

**Biodegradable polymers** Polylactic acid (PLA), Polyglycolic acid (PGA),

Polycaprolactone (PCL), Polyanhydrides, Polyorthoesters

**Non-biodegradable polymers** Polyethylene vinyl acetate (PVA), Polydimethylsiloxane (PDS), Polyether urethane (PEU), Polyvinyl chloride (PVC), Cellulose acetate (CA), Ethyl cellulose (EC)

**Mucoadhesive polymers** Polycarbophil, Sodium carboxymethyl cellulose, Polyacrylic acid, Tragacanth, Methyl cellulose, Pectin

**Natural gums** Xanthan gum, Guar gum, Karaya gum, Locust bean gum

#### Mechanism of Drug Release from Matrix Tablet<sup>30-32</sup>

Drug in the outside layer exposed to the bathing solution is dissolved first and then diffuses out of the matrix. This process continues with the interface between the bathing solution and the solid drug moving toward the interior. It follows that for this system to be diffusion controlled, the rate of dissolution of drug particles within the matrix must be much faster than the diffusion rate of dissolved drug leaving the matrix. Derivation of the mathematical model to describe this system involves the following assumptions:

- A pseudo-steady state is maintained during drug release,
- The diameter of the drug particles is less than the average distance of drug diffusion through the matrix,
- The bathing solution provides sink conditions at all times.

The release behaviour for the system can be mathematically described by the following equation:

$$dM/dh = C_0 \cdot dh - C_s/2 \dots\dots\dots (1)$$

Where,  $dM$  = Change in the amount of drug released per unit area

$dh$  = Change in the thickness of the zone of matrix that has been depleted of drug

$C_0$  = Total amount of drug in a unit volume of matrix

Cs = Saturated concentration of the drug within the matrix.

Additionally, according to diffusion theory:

$$dM = (D_m \cdot C_s / h) dt \dots\dots\dots (2)$$

Where, Dm = Diffusion coefficient in the matrix.

h = Thickness of the drug-depleted matrix

dt = Change in time

By combining equation 1 and equation 2 and integrating:

$$M = [C_s \cdot D_m (2C_o - C_s) t]^{1/2} \dots\dots\dots (3)$$

When the amount of drug is in excess of the saturation concentration then:

$$M = [2C_s \cdot D_m \cdot C_o \cdot t]^{1/2} \dots\dots\dots (4)$$

Equation 3 and equation 4 relate the amount of drug release to the square-root of time. Therefore, if a system is predominantly diffusion controlled, then it is expected that a plot of the drug release vs. square root of time will result in a straight line. Drug release from a porous monolithic matrix involves the simultaneous penetration of surrounding liquid, dissolution of drug and leaching out of the drug through tortuous interstitial channels and pores.

The volume and length of the openings must be accounted for in the drug release from a porous or granular matrix:

$$M = [D_s \cdot C_a \cdot p/T \cdot (2C_o - p \cdot C_a) t]^{1/2} \dots\dots (5)$$

Where, p = Porosity of the matrix

t = Tortuosity

Ca = solubility of the drug in the release medium

Ds = Diffusion coefficient in the release medium.

T = Diffusional path length

For pseudo steady state, the equation can be written as:

$$M = [2D \cdot C_a \cdot C_o (p/T) t]^{1/2} \dots\dots\dots (6)$$

The total porosity of the matrix can be calculated with the following equation:

$$p = p_a + C_a / \rho + C_{ex} / \rho_{ex} \dots\dots\dots (7)$$

Where, p = Porosity

ρ = Drug density

pa = Porosity due to air pockets in the matrix

ρex = Density of the water soluble excipients

Cex = Concentration of water soluble excipients

For the purpose of data treatment, equation 7 can be reduced to:

$$M = k \cdot t^{1/2} \dots\dots\dots (8)$$

Where, k is a constant, so that the amount of drug released versus the square root of time will be linear, if the release of drug from matrix is diffusion-controlled.

If this is the case, the release of drug from a homogeneous matrix system can be controlled by varying the following parameters:

- Initial concentration of drug in the matrix
- Porosity
- Tortuosity
- Polymer system forming the matrix
- Solubility of the drug

### Effect of Release Limiting Factor on Drug Release<sup>33-34</sup>

The mechanistic analysis of controlled release of drug reveals that partition coefficient; diffusivity; diffusional path thickness and other system parameters play various rate determining roles in the controlled release of drugs from either capsules, matrix or sandwich type drug delivery systems.

#### A. Polymer Hydration

It is important to study polymer hydration/swelling process for the maximum number of polymers and polymeric combinations. The more important step in polymer dissolution include absorption/adsorption of water in more accessible places, rupture of polymer-polymer linking with the simultaneous forming of water-polymer linking, separation of polymeric chains,

swelling and finally dispersion of polymeric chain in dissolution medium.

### **B. Drug Solubility**

Molecular size and water solubility of drug are important determinants in the release of drug from swelling and erosion controlled polymeric matrices. For drugs with reasonable aqueous solubility, release of drugs occurs by dissolution in infiltrating medium and for drugs with poor solubility release occurs by both dissolution of drug and dissolution of drug particles through erosion of the matrix tablet.

### **C. Solution Solubility**

In view of in vivo (biological) sink condition maintained actively by hem perfusion, it is logical that all the in vitro drug release studies should also be conducted under perfect sink condition. In this way a better simulation and correlation of in vitro drug release profile with in vivo drug administration can be achieved. It is necessary to maintain a sink condition so that the release of drug is controlled solely by the delivery system and is not affected or complicated by solubility factor.

### **D. Polymer Diffusivity**

The diffusion of small molecules in polymer structure is energy activated process in which the diffusant molecules moves to a successive series of equilibrium position when a sufficient amount of energy of activation for diffusion  $E_d$  has been acquired by the diffusant is dependent on length of polymer chain segment, cross linking and crystallinity of polymer. The release of drug may be attributed to the three factors viz, i. Polymer particle size ii. Polymer viscosity iii. Polymer concentration.

#### **i. Polymer Particle Size**

Malamataris stated that when the content of hydroxyl propyl methylcellulose is higher, the effect of particle size is less important on the release rate of propranolol hydrochloride, the effect of this variable more important when the content of polymer is low. He also justified

these results by considering that in certain areas of matrix containing low levels of hydroxyl propyl methylcellulose led to the burst release.

#### **ii. Polymer Viscosity**

With cellulose ether polymers, viscosity is used as an indication of matrix weight. Increasing the molecular weight or viscosity of the polymer in the matrix formulation increases the gel layer viscosity and thus slows drug dissolution. Also, the greater viscosity of the gel, the more resistant the gel is to dilution and erosion, thus controlling the drug dissolution.

#### **iii. Polymer Concentration**

An increase in polymer concentration causes an increase in the viscosity of gel as well as formulation of gel layer with a longer diffusional path. This could cause a decrease in the effective diffusion coefficient of the drug and therefore reduction in drug release. The mechanism of drug release from matrix also changes from erosion to diffusion as the polymer concentration increases.

### **E. Thickness of Polymer Diffusional Path**

The controlled release of a drug from both capsule and matrix type polymeric drug delivery system is essentially governed by Fick's law of diffusion:

$$JD = D \frac{dc}{dx}$$

Where, JD is flux of diffusion across a plane surface of unit area

D is diffusibility of drug molecule,

$dc/dx$  is concentration gradient of drug molecule across a diffusion path with thickness dx.

### **F. Thickness of Hydrodynamic Diffusion Layer**

It was observed that the drug release profile is a function of the variation in thickness of hydrodynamic diffusion layer on the surface of matrix type delivery devices. The magnitude of drug release value decreases on increasing the thickness of hydrodynamic diffusion layer  $\delta_d$ .

### G. Drug Loading Dose

The loading dose of drug has a significant effect on resulting release kinetics along with drug solubility. The effect of initial drug loading of the tablets on the resulting release kinetics is more complex in case of poorly water soluble drugs, with increasing initial drug loading the relative release rate first decreases and then increases, whereas, absolute release rate monotonically increases. In case of freely water soluble drugs, the porosity of matrix upon drug depletion increases with increasing initial drug loading. This effect leads to increased absolute drug transfer rate. But in case of poorly water soluble drugs another phenomenon also has to be taken in to account. When the amount of drug present at certain position within the matrix, exceeds the amount of drug soluble under given conditions, the excess of drug has to be considered as non-dissolved and thus not available for diffusion. The solid drug remains within tablet, on increasing the initial drug loading of poorly water soluble drugs, the excess of drug remaining within in matrix increases.

### H. Surface Area and Volume

The dependence of the rate of drug release on the surface area of drug delivery device is well known theoretically and experimentally. Both the *in vitro* and *in vivo* rate of the drug release, are observed to be dependent upon surface area of dosage form. Siepmann *et al.* found that release from small tablet is faster than large cylindrical tablets.

### I. Diluent's Effect

The effect of diluent or filler depends upon the nature of diluent. Water soluble diluents like lactose cause marked increase in drug release rate and release mechanism is also shifted towards Fickian diffusion; while insoluble diluents like dicalcium phosphate reduce the Fickian diffusion and increase the relaxation (erosion) rate of matrix. The reason behind this is that water soluble filler in matrices stimulate the water penetration in to inner part of matrix, due to increase in hydrophilicity of the system,

causing rapid diffusion of drug, leads to increased drug release rate.

### J. Additives

The effect of adding non-polymeric excipients to a polymeric matrix has been claimed to produce increase in release rate of hydrosoluble active principles. These increases in release rate would be marked if the excipients are soluble like lactose and less important if the excipients are insoluble like tricalcium phosphate.

### Biological Factors Influencing Release from Matrix Tablet<sup>33, 35</sup>

- Biological half-life.
- Absorption.
- Metabolism
- Distribution
- Protein binding
- Margin of safety

### Biological half-life

The usual goal of an oral SR product is to maintain therapeutic blood levels over an extended period of time. To achieve this, drug must enter the circulation at approximately the same rate at which it is eliminated. The elimination rate is quantitatively described by the half-life ( $t_{1/2}$ ). Each drug has its own characteristic elimination rate, which is the sum of all elimination processes, including metabolism, urinary excretion and all over processes that permanently remove drug from the blood stream. Therapeutic compounds with short half-life are generally are excellent candidate for SR formulation, as this can reduce dosing frequency. In general, drugs with half-life shorter than 2 hours such as furosemide or levodopa are poor candidates for SR preparation. Compounds with long half-lives, more than 8 hours are also generally not used in sustaining form, since their effect is already sustained. Digoxin and phenytoin are the examples.

### **Absorption**

Since the purpose of forming a SR product is to place control on the delivery system, it is necessary that the rate of release is much slower than the rate of absorption. If we assume that the transit time of most drugs in the absorptive areas of the GI tract is about 8-12 hours, the maximum half-life for absorption should be approximately 3-4 hours; otherwise, the device will pass out of the potential absorptive regions before drug release is complete. This corresponds to a minimum apparent absorption rate constant of 0.17-0.23h<sup>-1</sup> to give 80-95% over this time period. Hence, it assumes that the absorption of the drug should occur at a relatively uniform rate over the entire length of small intestine. For many compounds this is not true. If a drug is absorbed by active transport or transport is limited to a specific region of intestine, SR preparation may be disadvantageous to absorption. One method to provide sustaining mechanisms of delivery for compounds tries to maintain them within the stomach. This allows slow release of the drug, which then travels to the absorptive site. These methods have been developed as a consequence of the observation that co-administration results in sustaining effect. One such attempt is to formulate low density pellet or capsule. Another approach is that of bio adhesive materials.

### **Metabolism**

Drugs those are significantly metabolized before absorption, either in the lumen or the tissue of the intestine, can show decreased bioavailability from slower-releasing dosage form. Hence criteria for the drug to be used for formulating Sustained-Release dosage form is,

- Drug should have low half-life (<5 hrs.)
- Drug should be freely soluble in water
- Drug should have larger therapeutic window.
- Drug should be absorbed throughout the GIT

Even a drug that is poorly water soluble can be formulated in SR dosage form. For the same, the solubility of the drug should be increased by the

suitable system and later on that is formulated in the SR dosage form. But during this the crystallization of the drug, that is taking place as the drug is entering in the systemic circulation, should be prevented and one should be cautious for the prevention of the same.

### **Distribution**

Drugs with high apparent volume of distribution, which influence the rate of elimination of the drug, are poor candidate for oral SR drug delivery system e.g. Chloroquine.

### **Protein Binding**

The Pharmacological response of drug depends on unbound drug concentration drug rather than total concentration and all drug bound to some extent to plasma and or tissue proteins. Proteins binding of drug play a significant role in its therapeutic effect regardless the type of dosage form as extensive binding to plasma increase biological half-life and thus sometimes SR drug delivery system is not required for this type of drug.

### **Margin of safety**

As we know larger the value of therapeutic index safer is the drug. Drugs with less therapeutic index usually poor candidate for formulation of oral SR drug delivery system due to technological limitation of control over release rates.

### **Physicochemical Factors Influencing Release from Matrix Tablet<sup>33, 35</sup>**

#### **Dose size**

For orally administered systems, there is an upper limit to the bulk size of the dose to be administered. In general, a single dose of 0.5-1.0g is considered maximal for a conventional dosage form. This also holds for sustained release dosage form. Compounds that require large dosing size can sometimes be given in multiple amounts or formulated into liquid systems. Another consideration is the margin of safety involved in administration of large amount of a drug with a narrow therapeutic range.

### ***Ionization, Pka and Aqueous Solubility***

Most drugs are weak acids or bases. Since the unchanged form of a drug preferentially permeates across lipid membranes, it is important to note the relationship between the *pka* of the compound and the absorptive environment. Presenting the drug in an unchanged form is advantageous for drug permeation. Unfortunately, the situation is made more complex by the fact that the drug's aqueous solubility will generally be decreased by conversion to unchanged form. Delivery systems that are dependent on diffusion or dissolution will likewise be dependent on the solubility of the drug in aqueous media. These dosage forms must function in an environment of changing pH, the stomach being acidic and the small intestine more neutral, the effect of the release process must be defined. Compounds with very low solubility (<0.01mg/ml) are inherently sustained, since their release over the time course of a dosage form in the GI tract will be limited by dissolution of the drug. So it is obvious that the solubility of the compound will be poor choices for slightly soluble drugs, since the driving force for diffusion, which is the drug's concentration in solution, will be low.

### ***Partition Coefficient***

When a drug is administered to the GI tract, it must cross a variety of biological membranes to produce a therapeutic effect in another area of the body. It is common to consider that these membranes are lipidic; therefore the partition coefficient of oil-soluble drugs becomes important in determining the effectiveness of membrane barrier penetration. Compounds which are lipophilic in nature having high partition coefficient are poorly aqueous soluble and it retain in the lipophilic tissue for the longer time. In case of compounds with very low partition coefficient, it is very difficult for them to penetrate the membrane, resulting in poor bioavailability. Furthermore, partitioning effects apply equally to diffusion through polymer membranes. The choice of diffusion-

limiting membranes must largely depend on the partitioning characteristics of the drug.

### ***Stability***

Orally administered drugs can be subject to both acid-base hydrolysis and enzymatic degradation. Degradation will proceed at a reduced rate for drugs in solid state; therefore, this is the preferred composition of delivery for problem cases. For the dosage form that are unstable in stomach, systems that prolong delivery over entire course of transit in the GI tract are beneficial; this is also true for systems that delay release until the dosage form reaches the small intestine. Compounds that are unstable in small intestine may demonstrate decreased bioavailability when administered from a sustaining dosage form. This is because more drugs is delivered in the small intestine and, hence, is subject to degradation. Propentheline and prophanthine are representative example of such drug.<sup>18,36</sup>

### **CONCLUSION<sup>37</sup>**

By the above discussion, it can be easily concluded that sustained-release formulation are helpful in increasing the efficiency of the dose as well as they are also improving the patient's compatibility. More over all these comes with reasonable cost. The dosage form is easy to optimize and very helpful in case of the antibiotics in which irrational use of the same may result in resistance.

### **REFERENCES**

1. Chalo CSL, Robinson JR, Lee VHL. Sustained Release Drug Delivery Systems. Remington's Pharmaceutical Sciences. 17th ed. Mack; 1995.
2. Brahmkar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics a Treatise. 1st ed. New Delhi: Vallabh Prakashan; 1995.
3. Chein YW. Novel Drug Delivery Systems. 2nd ed., New York: Marcel Dekker; 1992:1-42.

4. Jain NK. Pharmaceutical Product Development. 1st ed., New Delhi: CBS Publishers and Distributors; 2006, 419-424.
5. Modi SA, Gaikwad PD, Bankar VH, Pawar SP. Sustained Release Drug Delivery System: A Review, *Int J Pharma. Res Dev* 2011, 2(12), 147-160.
6. Loyd V. Allen. Jr, Nicholas G. Popvich, Howard C. Ansel. *Ansel's Pharmaceutical dosage forms and drug delivery system*, 8th edition, 260-263.
7. Yie. *Novel Drug Delivery System*, Yie W.chain, 1992, 139-150.
8. Remington, the Science and practice of pharmacy, Lippincott Williams & Wilkins 20th edition, 2002, 903-914.
9. ME Aulton, "Pharmaceutics" The Science of dosage form design, Churchill Livingstone, 2nd edition, 2002.
10. Joshep R Robinson, Vincet H Lee. *Controlled drug delivery*, Marcel Dekker, 2nd edition, 1987, 4-15.
11. Altaf AS, Friend DR, MASRx and COSRx Sustained-Release Technology in Rathbone MJ, Hadgraft J, Robert MS, *Modified Release Drug Delivery Technology*, Marcell Dekker Inc., New York, 2003.
12. Vidyadhara S, Rao PR., Prasad JA. *Indian J.Pharm Sci*, 2004, 66, 188-192.
13. Reddy KR., Mutalik S, Reddy S. *AAPS Pharm. Sci. Tech.*, 2003, 4, 1-9.
14. Mohammed AD, James LF, Michael HR., John EH., Rajabi-Siahboomi AR. Release of propranolol hydrochloride from matrix tablets containing sodium carboxy methylcellulose and Hydroxypropyl methyl cellulose. *Phar. Dev. Tech.*, 1999, 4, 313-324.
15. Lee BJ, Ryu SG, Cui JH, *Drug Dev. Ind. Pharm.*, 1999, 25, 493-501.
16. Gwen MJ, Joseph RR, In Banker GS and Rhodes CT, Eds., *Modern Pharmaceutics*, 3rd Edn, Vol. 72, Marcel Dekker Inc. New York, 1996, 575.
17. Salsa T, Veiga F, Pina ME, *Drug Develop. Ind. Pharm.*, 1997, 23, 931.
18. Jantzen GM, Robinson JR, Sustained and controlled-release drug delivery systems, in Banker GS, Rhodes CT (Eds.) *Modern Pharmaceutics*, Third Edition, Revised and Expanded, *Drugs and the Pharmaceutical Sciences*, vol 72, Marcell Dekker, Inc. New York, 1995, 575-609.
19. Bechgaard H, Nielson GH. Controlled release multiple units and single unit dosage; *Drug Dev. & Ind. Pharm.*, 1978, 4(1), 53-67.
20. Alford N Martin, Patrick J. Sinko. *Martin's Physical pharmacy and pharmaceutical sciences*, 2006.
21. Lachman L, Lieberman HA, Kanig JL. *The theory and practice of Industrial pharmacy*, Verghesh publishing house, 3rd edition, 1990, 346.
22. Sayed I. Abdel-Rahman, Gamal MM, El-Badry M, Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets, *Saudi Pharmaceutical Journal*, 2009, 17, 283-288.
23. Chandran S, Laila FA, Mantha N, Design and evaluation of Ethyl Cellulose Based Matrix Tablets of Ibuprofen with pH Modulated Release Kinetics, *Indian Journal of Pharmaceutical Sciences*, September-October 2008.
24. Gothi GD, Parinh BN, Patel TD, Prajapati ST, Patel DM, Patel CN, *Journal of Global Pharma Technology*, 2010, 2(2), 69-74.
25. Basak SC, Reddy JBM, Lucas Mani KP. *Indian Journal of Pharmaceutical Sciences*, September-October 2006.
26. Varshosaz J, Tavakoli N and Kheirolahi. *AAPS PharmSciTech*, 2006, 7(1).
27. Raghvengra Rao NG, Gandhi S, Patel T. *International Journal of Pharmacy and Pharmaceutical Sciences*, 2009, 1(1).
28. Shivhare UD, Adhao ND, Dr. Bhusari KP, Dr. Mathur VB, Ambulkar UD. *International*

- Journal of Pharmacy and Pharmaceutical Sciences, 2009, 1(2).
29. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advances. Ist ed. Vallabh Prakashan, 2002, 156-189.
30. Borguist P, Korner A, Larsson A. A model for the drug release from a polymeric matrix tablets-effect of swelling and dissolution, J Controlled Release 2006, 113, 216-225.
31. Nishihata T, Tahara K, Yamamoto K. Overall mechanisms behind matrix sustained release (SR) tablets prepared with hydroxypropyl cellulose 2910, J Controlled Release, 1995, 35, 59-66.
32. Siepmann J, Peppas NA, HPMC matrices for controlled drug delivery: new model combining diffusion, swelling and dissolution mechanisms and predicting the release kinetics, Pharm Research 2000, 16, 1748-1756.
33. Brahmankar HA, Jaiswal SB, Biopharmaceutics and Pharmacokinetics A Treatise, Vallabh Prakashan, 2000, 348-357 and 337.
34. Wani MS, Controlled Release System- A Review, 2008, 6 (1), [www.pharmainfo.net/review](http://www.pharmainfo.net/review)
35. Shargel L, Yu ABC. Modified release drug products. In: Applied Biopharmaceutics and Pharmacokinetics. 4th ed. McGraw Hill. 1999, 169-171
36. ICH Guideline on Stability study; 2005.
37. Nandita GD, Sudip KD. Controlled-release of oral dosage forms, Formulation, Fill and Finish 2003, 10-16.

